Overview

Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this trial is to assess the efficacy and tolerability of memantine (anti-excitotoxic, neuroprotective treatment currently used in Alzheimer's disease [AD]) in frontotemporal dementia patients after a one-year treatment.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Nantes University Hospital
Treatments:
Memantine
Criteria
Inclusion Criteria:

- Patients with FTD based on the criteria defined by the Lund and Manchester groups'
consensus statement (revised in 1998), whose disease has been progressing during the
last year.

- MMSE score of 19 or higher

- Men and women aged 45 to 75 years

- Without speech, visuospatial, or episodic memory impairments

Exclusion Criteria:

- Age > 76 years

- Illiterate or misunderstanding patients

- Patients with cancer, heart disease, lung disease, kidney disease (creatinine > 200
mg/dL), or epilepsy